155 related articles for article (PubMed ID: 15671204)
21. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice.
Aasum E; Cooper M; Severson DL; Larsen TS
Can J Physiol Pharmacol; 2005 Feb; 83(2):183-90. PubMed ID: 15791292
[TBL] [Abstract][Full Text] [Related]
22. Perfusion of hearts with triglyceride-rich particles reproduces the metabolic abnormalities in lipotoxic cardiomyopathy.
Pillutla P; Hwang YC; Augustus A; Yokoyama M; Yagyu H; Johnston TP; Kaneko M; Ramasamy R; Goldberg IJ
Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1229-35. PubMed ID: 15701679
[TBL] [Abstract][Full Text] [Related]
23. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
24. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators.
Duncan JG; Bharadwaj KG; Fong JL; Mitra R; Sambandam N; Courtois MR; Lavine KJ; Goldberg IJ; Kelly DP
Circulation; 2010 Jan; 121(3):426-35. PubMed ID: 20065164
[TBL] [Abstract][Full Text] [Related]
25. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
[TBL] [Abstract][Full Text] [Related]
26. In vivo arterial lipoprotein lipase expression augments inflammatory responses and impairs vascular dilatation.
Takahashi M; Hiyama Y; Yokoyama M; Yu S; Hu Y; Melford K; Bensadoun A; Goldberg IJ
Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):455-62. PubMed ID: 18258818
[TBL] [Abstract][Full Text] [Related]
27. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
28. Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
Achanzar WE; Moyer CF; Marthaler LT; Gullo R; Chen SJ; French MH; Watson LM; Rhodes JW; Kozlosky JC; White MR; Foster WR; Burgun JJ; Car BD; Cosma GN; Dominick MA
Toxicol Appl Pharmacol; 2007 Sep; 223(3):246-56. PubMed ID: 17663016
[TBL] [Abstract][Full Text] [Related]
29. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.
Tanaka T; Masuzaki H; Ebihara K; Ogawa Y; Yasue S; Yukioka H; Chusho H; Miyanaga F; Miyazawa T; Fujimoto M; Kusakabe T; Kobayashi N; Hayashi T; Hosoda K; Nakao K
Metabolism; 2005 Nov; 54(11):1490-8. PubMed ID: 16253638
[TBL] [Abstract][Full Text] [Related]
30. Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation.
Festuccia WT; Laplante M; Brûlé S; Houde VP; Achouba A; Lachance D; Pedrosa ML; Silva ME; Guerra-Sá R; Couet J; Arsenault M; Marette A; Deshaies Y
J Mol Cell Cardiol; 2009 Jul; 47(1):85-95. PubMed ID: 19397913
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
Duhaney TA; Cui L; Rude MK; Lebrasseur NK; Ngoy S; De Silva DS; Siwik DA; Liao R; Sam F
Hypertension; 2007 May; 49(5):1084-94. PubMed ID: 17353509
[TBL] [Abstract][Full Text] [Related]
32. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
[TBL] [Abstract][Full Text] [Related]
33. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
Baraka A; AbdelGawad H
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):175-81. PubMed ID: 20133494
[TBL] [Abstract][Full Text] [Related]
34. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
35. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
Barbieri M; Di Filippo C; Esposito A; Marfella R; Rizzo MR; D'Amico M; Ferraraccio F; Di Ronza C; Duan SZ; Mortensen RM; Rossi F; Paolisso G
PLoS One; 2012; 7(4):e35999. PubMed ID: 22563432
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Luo Y; Yin W; Signore AP; Zhang F; Hong Z; Wang S; Graham SH; Chen J
J Neurochem; 2006 Apr; 97(2):435-48. PubMed ID: 16539667
[TBL] [Abstract][Full Text] [Related]
37. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
38. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity.
Dewald O; Sharma S; Adrogue J; Salazar R; Duerr GD; Crapo JD; Entman ML; Taegtmeyer H
Circulation; 2005 Jul; 112(3):407-15. PubMed ID: 16009788
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
